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Abstract
Objectives—The del Nido cardioplegia solution has been used extensively in congenital heart
surgery for more than 20 years and more recently for adults. This randomized controlled trial
examined whether expanding this technique to adult cardiac surgery confers benefits in surgical
workflow and clinical outcome compared with blood-based cardioplegia.
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Methods—Adult first-time coronary artery bypass grafting (CABG), valve, or CABG/valve
surgery patients requiring cardiopulmonary bypass (CPB) were randomized to del Nido
cardioplegia (n = 48) or whole blood cardioplegia (n = 41). Primary outcomes assessed myocardial
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preservation. Troponin I was measured at baseline, 2 hours after CPB termination, 12 and 24 hours
after cardiovascular intensive care unit admission. Alpha was set at P < .001.
Results—Preoperative characteristics were similar between groups, including age, Society of
Thoracic Surgeons risk score, CABG, and valve procedures. There was no significant difference
on CPB time (97 vs 103 minutes; P = .288) or cross-clamp time (70 vs 83 minutes; P = .018). The
del Nido group showed higher return to spontaneous rhythm (97.7% vs 81.6%; P = .023) and
fewer patients required inotropic support (65.1% vs 84.2%; P = .050), but did not reach statistical
significance. Incidence of Society of Thoracic Surgeons-defined morbidity was low, with no
strokes, myocardial infarctions, renal failure, or operative deaths. For del Nido group patients,
troponin levels did not increase as much as for control patients (P = .040), but statistical
significance was not reached.
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Conclusions—Evidence from this study suggests del Nido cardioplegia use in routine adult
cases may be safe, result in comparable clinical outcomes, and streamline surgical workflow. The
trend for troponin should be investigated further because it may suggest superior myocardial
protection with the del Nido solution.

Graphical abstract
Mean troponin I levels by treatment group from presurgery to 24 hours after cardiovascular
intensive care unit (CVICU) admission.
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Optimal myocardial protection during cardiac surgery is a key component of a successful
procedure.1 Since the 1950s, research and strategies have been developed to continuously
improve myocardial protection and prevent further ischemic injury.2–4 The use of
hypothermic and hyperkalemic cardioplegia solutions evolved to become the clinical
standard in many cardiac surgery programs across the world.5 Despite the multitude of
reported cardioplegia systems, there is a lack of clear consensus on composition, route, and
technique.1,5,6
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A novel formula for cardioplegia was introduced in congenital heart surgery in 1995.7 This
formula was patented as a single dose and modified depolarizing solution. Now commonly
referred to as del Nido solution, this blood and crystalloid mixed formula has been
associated with a longer duration of safe myocardial ischemic arrest.8,9 This solution has
been purported to preserve intracellular high-energy phosphates and intracellular pH and
reduce calcium ion influx during and after ischemic arrest and led to its increased use across
pediatric congenital cardiac surgery programs.10,11

Author Manuscript

Multiple observational studies have suggested that the del Nido solution is associated with
safety and efficacy in adult surgical procedures.12–18 Despite these encouraging findings,
adaptation of the protocol in treating adult ischemic myocardium has not been addressed by
prospective randomized trials.19 The purpose of this prospective randomized controlled trial
was to compare the del Nido cardioplegia protocol with an existing whole blood-based
cardioplegia strategy in routine coronary artery bypass grafting (CABG), valve, and CABG/
valve surgery procedures.

METHODS

Author Manuscript

After obtaining institutional review board approval (study No.14-1653), adult patients
presenting for first-time CABG or heart valve surgery requiring cardiopulmonary bypass
(CPB) between February 2015 and April 2016 were eligible to participate (study No.
NCT02442050). Inclusion criteria included adult patients aged 19 to 79 years; patients able
to receive and provide informed consent; stable patients with surgical procedures requiring
CPB and myocardial arrest; and isolated CABG surgery, isolated single-valve surgery, or
concomitant CABG and single-valve surgery. Exclusion criteria included previous cardiac
surgery, patients with preoperative inotropic pharmacologic support, patients receiving
preoperative mechanical circulatory support, patients with an implanted pacemaker or
implantable cardioverter-defibrillator, and patients undergoing cardiac surgical procedures
outside of the inclusion criteria categories.

Author Manuscript

Patients completed written informed consent and were randomized to receive del Nido
cardioplegia solution or whole blood cardioplegia. There were 2 arms for randomization in
this trial to ensure equitable representation of surgical procedures in each treatment group:
all eligible patients undergoing any heart valve surgical procedure with or without CABG
surgery, and all eligible patients undergoing CABG surgery. Within each arm, patients were
randomized to the intervention group (del Nido solution) or the control group (whole blood
cardioplegia) using random number generation and blocked randomization with groups of
20. The randomization order was created before enrollment began and was then transferred
to sealed consecutively numbered envelopes by a member of the study team who was not
involved in patient enrollment. Of 99 patients who provided written informed consent and
were enrolled in the study, 90 were randomized to a treatment group and 9 patients withdrew
or had surgery canceled. Randomization occurred the day before the originally scheduled
surgery date. One patient randomized to the control group was excluded because surgery
was canceled. Therefore, 89 patients were included in these analyses (Figure 1) with 48 in
the del Nido group and 41 in the control group.
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Primary outcome measures assessed myocardial preservation by return to spontaneous
rhythm; defibrillation requirement; inotropes; and troponin levels at 4 time points: baseline
(at anesthesia induction), 2 hours after termination of CPB, 12 hours after admission to a
cardiovascular intensive care unit (CVICU), and 24 hours after admission to a CVICU.
Secondary outcomes assessed safety and workflow, including CPB and cross-clamp time,
cardioplegia redosing, blood transfusion, and electrocardiogram changes 1 day after surgery.
Postoperative clinical outcomes were defined by the Society of Thoracic Surgeons (STS)
Adult Cardiac Surgical Database. Calculated ejection fraction was assessed using
transesophageal echocardiography (TEE) before surgery and at the termination of CPB.
CPB and Cardioplegia Delivery
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Author Manuscript

For these patients, CPB was conducted with the Terumo Advanced System I Extracorporeal
Perfusion System (Terumo Cardiovascular Group, Ann Arbor, Mich). All CPB circuits
consisted of a Terumo RX series oxygenator and hardshell reservoir, an AF-125 arterial
filter, and Xcoating surface coating. Patients with a body surface area < 1.9 m2 received a
Terumo RX-15 oxygenator and 3/8-in arterial and venous tubing, whereas patients with a
body surface area ≥ 1.9 m2 were supported with a Terumo RX-25 oxygenator and 1/2-in
venous tubing. Heparin dosing and anticoagulation was calculated using the Medtronic
Hemostasis Management System (Medtronic, Minneapolis, Minn). Acute normovolemic
hemodilution and retrograde autologous prime were performed on all patients deemed
hemodynamically stable to donate and able to maintain a CPB hematocrit of at least 21%.
Target hypothermic systemic temperatures on CPB support were maintained between 32°C
and 35°C. The use of cardiotomy pump suction was limited to intracardiac blood collected
during heart valve procedures. The Fresenius Continuous Autotransfusion System
(CATSplus; Fresinius KABI AG, Bad Homburg, Germany) was used to process surgical shed
blood and residual CPB circuit volume after bypass was complete.

Author Manuscript

The del Nido and whole-blood cardioplegia formulas were delivered through the Quest
Medical Myocardial Protection System II (Quest Medical Inc, Allen, Tex) (Table 1). Patients
enrolled in the intervention group received 1.0 L del Nido cardioplegia after the aortic crossclamp was applied to the ascending aorta (Central Admixture Pharmacy Services Inc,
Bethlehem, Pa). An additional 500 mL was administered if left ventricular hypertrophy was
present per the discretion of the attending surgeon. When a retrograde dose of cardioplegia
through a coronary sinus catheter was requested by the surgeon, the calculated induction
dose was equally split between antegrade and retrograde routes. Although not required for
the study protocol, all patients received both antegrade and retrograde administration per
standard of care. Subsequent doses of del Nido were not indicated unless the ischemic
duration exceeded 90 minutes or there was spontaneous return of electrical activity during
the aortic cross-clamp period. If a subsequent dose of del Nido was required, an additional
500 mL was administered. Delivery of del Nido solution was administered in a 1:4 ratio of
blood to crystalloid at a temperature of 6°C to 10°C. Topical cooling was applied in all
cases.
Patients enrolled in the control group received whole blood cardioplegia according to the
institutional adult cardioplegia protocol. No additional crystalloid solution was added to the

J Thorac Cardiovasc Surg. Author manuscript; available in PMC 2019 March 01.

Ad et al.

Page 5

Author Manuscript

mircoplegia formula; rather, potassium chloride and magnesium sulfate were titrated into the
blood delivery. The dose and frequency of delivery was administered according to surgical
protocol. The induction dose of whole blood cardioplegia ranged from 1.0 to 2.0 L of
solution, with subsequent doses of cardioplegia approximately every 20 minutes.
Cardioplegia doses were administered at a temperature of 8°C to 11°C. Before removal of
the aortic cross-clamp, a dose of amino acid-enriched warm cardioplegia solution,
monosodium aspartate, and glutamate was provided, as well as a systemic bolus of 1%
lidocaine sulfate of 2 mg/kg (maximum dose of 200 mg). TEE was used to perform pre- and
post-CPB left ventricular ejection fraction calculations. The need for pharmacologic postCPB inotropic support was at the discretion of the surgeon and anesthesiologist.
Troponin Assessment
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Blood was collected from patients to perform serum troponin assays at 4 scheduled time
points: at anesthesia induction, 2 hours after the discontinuation of CPB, 12 hours after
admission into the CVICU, and 24 hours after admission to the CVICU. The Architect Stat
Troponin-I assay (Abbott Laboratories, Abbott Park, Ill) is a 2-step immunoassay to
determine the presence of cardiac troponin in human plasma using chemiluminescent
microparticle immunoassay technology.
Statistical Analyses
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All analyses were conducted using IBM SPSS Statistics version 24.0 (IBM Corp, Armonk,
NY). Noninferiority analyses were originally planned for the primary study outcomes
assuming there would be no differences between the 2 treatments. Power analyses indicated
a sample size of 500 patients (n = 250 per group) would be sufficient to support
noninferiority of del Nido with the originally planned analyses using a 5% acceptable
difference margin (noninferiority limit) based on previous data from Ovrum and colleagues.1
However, when interim analyses that were built into the protocol for data safety monitoring
were conducted to assess the safety of the treatment arms, meaningful differences beyond
noninferiority were found. Analyses were therefore shifted to a superiority methodology to
assess the differences further and the study was stopped at this point. Based on results of the
interim analyses presented here, there was no justification to continue the study for
noninferiority objectives given the differences in outcomes. Subsequently, a post hoc alpha
spending function using the Lan-DeMets method was applied to evaluate how the alpha level
was affected by stopping the study at this point.20,21 An alpha level of P < .001 was
determined to be required at this point in the study for statistical significance to be achieved.
Therefore, only a P value of < .001 two-tailed was considered statistically significant.
However, given the preliminary nature of this study, results that suggest potential for
statistical significance at a traditional alpha level of P < .05 in a larger study are reported.
Continuous data are presented as mean ± standard deviation or median (interquartile range)
and categorical data are presented as frequency (%). Analyses comparing patient
characteristics and outcomes by treatment group included independent-sample t tests or the
Mann-Whitney U test for continuous variables and χ2 or Fisher exact tests for categorical
variables. A repeated measures analysis of variance testing the main effect of time, the main
effect of treatment, and the time × treatment interaction was conducted to examine the
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change in troponin levels over the 4 time points by treatment group. Complete data on all 4
time points was required for this analysis and listwise deletion was employed for patients
with missing troponin data (control n = 2 and del Nido n = 3). Linear regression evaluated
the effect of treatment group on ejection fraction at the termination of CPB after adjustment
for preoperative ejection fraction.

RESULTS
The treatment groups were similar on all preoperative clinical characteristics, including age
(65.3 vs 65.1 years), STS risk score (1.4% vs 1.3%), CABG surgery (75% vs 66%), and
valve procedures (40% vs 39%) (Table 2).
Primary Outcomes

Author Manuscript

The del Nido group had a greater proportion of patients who returned to spontaneous rhythm
than the control group (97.7% vs 81.6%; P = .023), but this result did not reach statistical
significance. Defibrillation after coronary reperfusion was similar between the del Nido and
control groups (4.7% vs 13.2%; P = .244) and there was also no difference between the del
Nido and control groups on the median number of defibrillation attempts required (z =
−1.31; P = .190). Fewer patients in the del Nido group required inotropic support compared
with the control group (65.1% vs 84.2%; P = .050). Repeated measures analysis of all 4 time
points found that for the del Nido group, troponin levels after surgery did not increase as
much as for the control group (F = 4.1; P = .040) (Figure 2), but this interaction term did not
reach statistical significance. By 24 hours after admission to the CVICU, troponin levels
reached 7.0 ± 14.7 in the control group whereas troponin levels were 2.3 ± 2.1 in the del
Nido group (P = .053).
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Secondary Outcomes
There was no difference between the del Nido group and control group on CPB time (97 vs
103 minutes; P = .288), and although cross-clamp time was shorter for the del Nido group
(70 vs 83 minutes; P = .018), the comparison did not reach statistical significance. After
adjustment for preoperative ejection fraction measured by TEE, regression analysis found
that the del Nido and control groups were similar on postoperative ejection fraction
measured by TEE (t = 0.3; P = .787).

Author Manuscript

Incidence of STS-defined morbidity was low, with no strokes, perioperative myocardial
infarctions, renal failure, or operative deaths in either group. The composite outcome of any
STS-defined complication appeared lower for the del Nido group, although the analysis did
not reach statistical significance (11.6% vs 26.3%; P = .089). The proportion of patients with
blood transfusions was similar for the del Nido and control groups (4% vs 7%; P = .658), as
was mean hematocrit at discharge (31.6% ± 4.9% vs 31.8% ± 4.5%; P = .882). None of the
patients had a new Q wave on electrocardiogram and only 1 control group patient showed
ST-segment elevation.
The mean total volume of cardioplegia solution administered was significantly lower for the
del Nido groups compared with the control group (1746.2 ± 852.5 mL vs 5077.8 ± 2475.4
mL; P < .001). The amount of crystalloid used in the mean volume of del Nido solution
J Thorac Cardiovasc Surg. Author manuscript; available in PMC 2019 March 01.
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(1746.2 mL) was 1396.6 mL. This amount was calculated using a 1:4 ratio of blood to
crystalloid. The amount of crystalloid used in the mean volume of microplegia (5077.8 mL)
was 114 mL. This was calculated by adding the calculated amount of 44 mL potassium
chloride, 40 mL magnesium sulfate, and 30 mL substrate-enriched monosodium aspartate/
monosodium glutamate additive. Similarly, the median number of cardioplegia doses
administered was also significantly lower for the del Nido group in comparison to the
control group (1 [interquartile range, 1–2] vs 5 [interquartile range, 4–7]; z = −7.39; P < .
001). For the del Nido group, 28% required more than one dose of cardioplegia, whereas
100% of the control group required > 1 dose (P < .001).

DISCUSSION

Author Manuscript
Author Manuscript

The findings from this study indicate that the use of del Nido cardioplegia in both adult
CABG and valve surgeries can be administered safely and with comparable levels of
myocardial injury and inotropic support, and may yield significant benefits in surgical
workflow in certain types of surgeries and surgical approaches. These findings are consistent
with several previously reported observational studies. Although there are a multitude of
cardioplegia formulas and techniques reported in the scientific literature, few studies
compare the effects in a controlled prospective study design. Previous randomized controlled
trials in myocardial protection have been limited to multidose and depolarizing cardioplegia
solutions. A prospective, randomized study has yet to be performed on single-dose modified
depolarizing strategies. The purpose of the present study was to compare the use of del Nido
cardioplegia delivery to our current whole blood-based delivery protocol with the initial
hypothesis that del Nido solution would be noninferior to our conventional strategy in both
myocardial functional recovery and perioperative clinical outcome. Not only did our
analyses support this hypothesis, but may also indicate some improvement in surgical
workflow, such as shorter CPB and cross-clamp times and fewer doses of cardioplegia.

Author Manuscript

In a propensity score-matched review of consecutive patients presenting at New York
Presbyterian Hospital for reoperative aortic valve replacement surgery, Sorabella and
colleagues18 found no significant differences in perioperative patient outcome between
whole blood and del Nido cardioplegia protocols. The del Nido group received significantly
less cardioplegia volume and the need for retrograde cardioplegia delivery. Researchers from
the same institution analyzed 88 consecutive patients who presented with acute myocardial
infarction for CABG surgery. Yerebaken and colleagues12 concluded no differences between
the del Nido and whole blood cardioplegia groups in postoperative outcome. However,
significant reductions in CPB duration and aortic cross-clamp time were realized in that
high-risk cohort of patients.12 In another propensity score-matched review of 100
consecutive patients presenting for CABG surgery, Timek and colleagues13 compared
outcome between del Nido cardioplegia and their conventional blood cardioplegia protocol.
Despite the significant differences in total cardioplegia volume, number of doses, and route
of delivery, del Nido cardioplegia delivered as a single antegrade dose provided equivalent
myocardial protection in patients undergoing coronary revascularization.
The decision to use del Nido for patients with multivessel coronary artery disease has been a
reported concern for programs, even those who routinely employ del Nido solution for other
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heart procedures.22 The maldistribution of cardioplegia delivery due to severe coronary
disease may prevent penetration in ischemic areas of the myocardium. Strategies to provide
uniform hypothermia of the heart may include retrograde cardioplegia, cardioplegia delivery
down the saphenous vein grafts, and topical hypothermia. The use of retrograde cardioplegia
at our institution has been considered a standard for the majority of patients presenting for
CABG surgery. For retrograde administration, we elected to halve the dose of del Nido
cardioplegia between routes to ensure proper distribution and arrest. Further, the use of
topical ice lavage during valve procedures was also used at the discretion of the surgeon.
Although we did not directly monitor myocardial temperature, we believe we adequately
addressed our own concerns in ensuring uniform distribution and subsequent tissue
warming.

Author Manuscript
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Perioperative cardiac troponin levels did not increase as high in the del Nido group
compared with the whole blood control group. At the 24-hour postoperative interval,
troponin levels in the whole blood group failed to demonstrate a true peak value, whereas the
trend in the del Nido group showed a decrease in biomarker production. According to the
National Academy of Clinical Biochemistry Medicine Practice Guidelines, the time to first
increase for cardiac troponin levels is approximately 3 to 4 hours, with peak levels occurring
at approximately 18 hours after the onset of symptoms.23–25 Accordingly, we scheduled our
biomarker assays to capture the initial ischemic insult, postoperative elevation and peak
levels within the first 24 hours postsurgery. Other del Nido studies failed to show significant
differences in blood troponin levels between study groups, but it may be related to the
retrospective nature of the studies and the lack of standardization in the samples regarding
time intervals and the number of tests.14,16 We believe the trend for a difference in peak
troponin release may be multifactorial. First, the lower hematocrit in del Nido may have
provided improved distribution throughout the microcirculation. As temperature decreases,
the viscosity of whole blood increases. Our whole blood-based cardioplegia protocol may
not have provided equal distribution of cardioplegia volume at hypothermic infusion
temperatures. In vitro models have explained the profound influence that altering hematocrit
and temperature change have on blood viscosity and fluid distribution.26 The resultant
hematocrit delivery of del Nido was estimated between 6% and 7%, whereas the hematocrit
of whole blood cardioplegia was estimated to be delivered between 26% and 32%.
Lidocaine may also have a direct influence on tissue vasoactivity and microvascular
response through action potential inhibition and increased nitric oxide release.27
Furthermore, we recognize the potential benefits that lidocaine may provide in preserving
intracellular pH and limiting calcium ion influx. Our conventional whole blood technique
did not include lidocaine as an additive; rather, a systemic bolus of 1% lidocaine was
administered before removal of the aortic cross-clamp. The prolonged action of lidocaine
when used in the cardioplegia formula may provide improved myocyte preservation during
ischemic arrest.7,28 Although the whole blood technique did incorporate magnesium sulfate
as a natural calcium antagonist, the combined delivery of lidocaine and magnesium in del
Nido may have provided further protection from injury. By inhibiting the influx of
intracellular protons through sodium channel blockade and buffering agents such as carbonic
anhydrase, glycogen stores inside the cells can be used to provide additional ATP stores
during ischemia. Similar observations were reported by Gustavo and Voolaran.17,19
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However, a retrospective analysis performed at Brigham and Women’s Hospital29 reported
that the presence of lidocaine in their modified del Nido formula was associated with a 4- to
5-fold increase in postoperative creatine kinase-MB values when compared with their
standard whole blood cardioplegia. Despite these increases, operative and 1-year mortality
rates were similar between groups. The authors concluded that lidocaine-containing
cardioplegia can be administered safely for the first 60 minutes of aortic cross-clamping. We
believe a larger, controlled study of various lidocaine-enriched cardioplegia strategies is
warranted. Future studies should include a more specific perioperative echocardiography
protocol. More specifically, an intraoperative echocardiogram as a single assessment for
myocardial function is likely not sufficient and additional tests at day 2 or 3 and 5 could
provide better evidence. We also believe that future studies should include specific
assessment for subendocardial function such as global longitudinal strain 24 hours before
and 2 to 3 days after surgery. Global longitudinal strain is a very sensitive marker for
subendocardial function and is well validated.
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Mean aortic cross-clamp duration was shorter in the del Nido group. Although not
statistically significant, this finding was attributed to the need for the surgeon to
intermittently stop and deliver maintenance doses of cardioplegia in conventional
depolarizing solutions. This finding was consistent with other studies comparing del Nido
cardioplegia to conventional techniques, as well as other single-dose crystalloid strategies
such as Custodiol (Essential Pharmaceuticals, LLC, Durham, NC).19,30 Although we
realized a reduction in CPB duration, this difference also did not reach statistical
significance. Continued expansion of del Nido into more complex patient and surgical
profiles may further improve surgical workflow, including shorter CPB and cross-clamp
times and fewer doses of cardioplegia.

Author Manuscript

Limitations
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There were several limitations to our study. We compared the use of del Nido to our current
whole blood cardioplegia protocol. Our findings may not be generalizable to the broader
surgical community, because the multitude of variations in cardioplegia technique may not
provide comparable results. Other del Nido comparative studies use more commonly
reported Buckberg cardioplegia formulas as controls. In addition, the lack of surgical team
blinding could introduce a source of bias to some of the outcome measures, although these
variables were not captured by the surgical team and the surgical team did not have
consensus regarding the preferred myocardial preservation method to be applied. The
indications for inotropes were not standardized in this study and therefore may not represent
an unbiased measure of myocardial protection. We also were unable to confirm a peak
troponin value in the control group at 24 hours. Troponin values may have peaked even
higher than what was reported in our analysis. We were unable to determine the long-term
outcomes associated with elevated postoperative troponin values. Additionally, our
eligibility criteria excluded high-risk cardiac surgery patients. Patients with previous cardiac
surgery, requiring pharmacologic and mechanical cardiac support, and patients older than
age 80 years were not considered for study. Further, the mean aortic cross-clamp times were
70 and 83 minutes for the del Nido and whole blood groups, respectively. As such, we were
unable to substantiate the effects of del Nido for prolonged periods of arrest beyond 2 hours.
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Another limitation of this study is the small sample size, which influenced the power of
some analyses. Given the interim analysis status for these results, a post hoc alpha spending
function was applied and only comparisons that reached P < .001 were considered
statistically significant. The use of this technique in combination with the small sample size
resulted in not rejecting the null hypothesis for some analyses that met an unadjusted alpha
level. In addition, although the results of the troponin analyses found a greater increase in
values for the control group, the result did not reach statistical significance and observed
power was 56% for this analysis, which requires replication in future studies for validation.
However, we believe that these findings, in conjunction with previous retrospective
literature, can serve as pilot data to support the undertaking of a larger randomized
controlled trial, perhaps expanding the patient population and surgical procedures included.

CONCLUSIONS
Author Manuscript

Evidence from this study supports previous literature that suggests expanding the use of del
Nido cardioplegia to routine adult cases may be safe and could improve streamline surgical
workflow with comparable clinical outcomes. The difference in troponin levels should be
investigated further because it may reflect myocardial protection associated with del Nido
solution versus blood cardioplegia, especially in regard to vasodilation and microvascular
response.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CABG

coronary artery bypass grafting

CPB

cardiopulmonary bypass

CVICU

cardiovascular intensive care unit

STS

Society of Thoracic Surgeons

TEE

transesophageal echocardiography
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Central Message
Evidence from this initial randomized controlled trial suggests use of del Nido
cardioplegia in routine adult cases may be safe, have comparable clinical outcomes, and
streamline surgical workflow.
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Perspective
The del Nido cardioplegia solution has been used extensively in congenital heart surgery
for more than 20 years. Recent literature has suggested that del Nido solution may be
administered safely in adult surgical procedures. Results of this randomized trial support
previous studies on safety of del Nido solution and suggest comparable results for
myocardial injury and potential benefits in surgical workflow.
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FIGURE 1.
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Enrollment flow diagram. CABG, Coronary artery bypass grafting.
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FIGURE 2.

Mean ± standard error troponin I levels in the 2 treatment groups from presurgery to 24
hours after cardiovascular intensive care unit (CVICU) admission. CPB, Cardiopulmonary
bypass.
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Cardioplegia formulas and strategy by treatment group
Formula

del Nido (treatment)

Whole blood (control)

Carrier solution

Plasmalyte-A (1000 mL)

Whole blood

Blood:crystalloid

1:4

Whole blood with titration

Potassium chloride

26 mEq

25 mEq/L induction
6–10 mEq/L maintenance

Mannitol (20%)

3.26 g

0

Lidocaine (1%)

130 mg

0

Magnesium sulfate (50%)

2g

1 mg/mL induction
0.5 mg/mL maintenance

Sodium bicarbonate (8.4%)

13 mEq

0

Monosodium aspartate/Glutamate (0.92 molar)

0

50 mL/L
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Author Manuscript

Patient characteristics by treatment group
Characteristic

Author Manuscript
Author Manuscript

Control group (n = 41)

del Nido group (n = 48)

P value

Age (y)

65.1 ± 9.1

65.3 ± 7.9

.885

Female

10 (24)

8 (17)

.366

Body mass index

30.6 ± 5.0

30.2 ± 6.2

.779

Ejection fraction (%)

57.6 ± 11.4

54.3 ± 11.9

.187

Diabetes

15 (37)

22 (46)

.378

Hypertension

32 (78)

35 (73)

.576

Peripheral vascular disease

4 (10)

2 (4)

.408

Cerebrovascular disease

5 (12)

6 (13)

.965

Chronic pulmonary disease

17 (42)

21 (44)

.828

Dyslipidemia

36 (88)

41 (85)

.742

Preoperative creatinine

1 (0.8–1.2)

1 (0.8–1.2)

.794

Preoperative hematocrit (%)

39.2 ± 5.9

39.3 ± 4.8

.900

STS risk score (%)

1.3 ± 1.1

1.4 ± 1.0

.859

Elective status

29 (71)

35 (73)

.819

CABG surgery

27 (66)

36 (75)

.344

25 (61)

29 (60)

.957

2 (5)

7 (15)

.170

Isolated CABG surgery
CABG/valve surgery
Valve surgery

16 (39)

19 (40)

.957

Aortic valve

15 (37)

14 (29)

.457

Mitral valve

1 (2)

5 (10)

.212

Values are presented as mean ± standard deviation, median (interquartile range), or n (%). STS, Society of Thoracic Surgeons; CABG, coronary
artery bypass grafting.

Author Manuscript
J Thorac Cardiovasc Surg. Author manuscript; available in PMC 2019 March 01.

